We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
11 January 2021Immunocore announces closing of $75.0 Million Series C round
3 December 2020Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
23 November 2020Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma